Automated cervical cancer screening device "too expensive"
This article was originally published in Clinica
Neuromedical Systems' automated cervical cancer screening device, Papnet, is not much better than manual Pap smear testing despite being up to 30 times more costly, a new study has claimed.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.